Meridian Bioscience Inc
VIVO
VIVO was delisted on the 30th of January, 2023.
170 hedge funds and large institutions have $1.06B invested in Meridian Bioscience Inc in 2013 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 50 increasing their positions, 64 reducing their positions, and 16 closing their positions.
69% more call options, than puts
Call options by funds: $421K | Put options by funds: $249K
25% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 16
11% more capital invested
Capital invested by funds: $956M → $1.06B (+$102M)
2% more funds holding
Funds holding: 166 → 170 (+4)
22% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 64
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$12.6M |
| 2 |
BCM
Brown Capital Management
Baltimore,
Maryland
|
+$9.23M |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
+$4.2M |
| 4 |
Morgan Stanley
New York
|
+$3.06M |
| 5 |
CCA
Conestoga Capital Advisors
Wayne,
Pennsylvania
|
+$2.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DRZID
DePrince Race & Zollo Inc (DRZ)
Winter Park,
Florida
|
-$11.8M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$10.3M |
| 3 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
-$9.98M |
| 4 |
Schroder Investment Management Group
London,
United Kingdom
|
-$4.63M |
| 5 |
CPCM
Clifton Park Capital Management
Wilmington,
Delaware
|
-$4.47M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
PP
176
PDT Partners
New York
| – | -$727K | -30,736 | Closed |
|
177
ProShare Advisors
Bethesda,
Maryland
| – | -$641K | -27,092 | Closed |
|
178
Arrowstreet Capital
Boston,
Massachusetts
| – | -$330K | -13,956 | Closed |
|
179
SG Americas Securities
New York
| – | -$174K | -7,347 | Closed |
|
|
TRCT
180
Tower Research Capital (TRC)
New York
| – | -$58K | -2,480 | Closed |
|
|
SFSIG
181
San Francisco Sentry Investment Group
San Francisco,
California
| – | -$37K | -1,580 | Closed |
|
|
HR
182
Howe & Rusling
Rochester,
New York
| – | -$26K | -1,096 | Closed |
|
|
RNS
183
Robert N. Shapiro
| – | -$25K | -1,075 | Closed |
|
|
PCM
184
Prelude Capital Management
New York
| – | -$9K | -390 | Closed |
|
|
AA
185
AlphaMark Advisors
Ft. Wright,
Kentucky
| – | -$5K | -193 | Closed |
|
|
QT
186
Quantbot Technologies
New York
| – | -$2K | -100 | Closed |
|
VIVO Hedge Fund Activity: Q4 2013 in Review
170 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Meridian Bioscience Inc (VIVO) for Q4 2013, worth a combined $1.06B — up 11% from $956M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new VIVO positions and 16 closed out — a net gain of 4 holders — while 50 added to existing stakes and 64 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $12.6M. The largest seller was DePrince Race & Zollo Inc (DRZ), exiting entirely with an estimated $11.8M sold.
- 170 institutional investors held Meridian Bioscience Inc (VIVO) as of Q4 2013, up from 166 in Q3 2013.
- Funds reported $1.06B of Meridian Bioscience Inc stock for Q4 2013, up 11% quarter-over-quarter.
- 20 funds opened new Meridian Bioscience Inc positions in Q4 2013 and 16 closed out, a net change of +4 holders.
- The largest Meridian Bioscience Inc buyer in Q4 2013 was Fidelity Investments, an estimated $12.6M added.
- The largest Meridian Bioscience Inc seller in Q4 2013 was DePrince Race & Zollo Inc (DRZ), an estimated $11.8M sold.
Based on aggregated 13F filings for Q4 2013.